

**Identity:**

Title: MD, FESC, FACC  
 Family Name(s): AMIR  
 First Name(s): OFFER  
 Age: 59

**Application for the following position in the HFA  
 Board or Nominating Committee:**

Treasurer

**Photo:****Place of work**

*If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.*

Institute/organisation:	HADASSAH MEDICAL CENTER
Department:	Director, Heart Institute
Address:	JERUSALEM, ISRAEL
Post code / Zip:	9112001
Country:	ISRAEL

**General Curriculum Vitae (500 words max)**

*Please also include your H index and top 5 to 10 publications in the last 5 years*

**CURRENT APPOINTMENTS:**

**Director, Heart Institute, Hadassah Medical Center, Jerusalem, Israel**

**Professor of Cardiovascular Medicine, Faculty of Medicine, Hebrew University**

**Immediate past president, Israel Heart Society**

### **Major Professional experience:**

Residency in Internal Medicine, Texas Medical Center, University of Texas, Houston, TX, USA  
Completed with excellence

Chief Medical Resident, Texas Medical Center, University of Texas, Houston, TX, USA

Fellowship in Heart Failure/Heart Transplant, Texas Heart Institute, Baylor College of Medicine, Houston, TX, USA, Fellowship certified by the United Network for Organ Sharing (UNOS)

### **Publications (11):**

1. Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, Olsha-Castell S, Arad D, Hasin T, Le Asleh R, **Amir O**, Meir K, Cohen D, Dichtiar R, Novick D, Hershkovitz Y, Dagan R, Leitersdorf I, Ami R, Miskin I, Saliba W, Muhsen K, Levi Y, Green MS, Keinan-Boker L, Alroy-Preis S. Myocardial injury after BNT162b2 mRNA Vaccine against Covid-19 in Israel. *N Engl J Med*. 2021 Dec 2;385(23):2140-50.
2. **Amir O**, Abraham WT, Azzam ZS, Berger G, Anker SD, Pinney SP, Burkhoff D, Shallom ID, Lotan R, Edelman ER. Remote Speech Analysis in the Evaluation of Hospitalized Patients With Acute Decompensated Heart Failure. *JACC Heart Fail*. 2022 Jan;10(1):41-49.
3. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, **Amir O**. (2012) Serum levels of microRNAs in patients with heart failure. *Eur J Heart Fail*. 14(2):147-54.
4. Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, **Amir O**, Chioncel O<sup>C</sup>, McMurray JJ<sup>C</sup>, Drozdz J<sup>C</sup>, Erglis A<sup>C</sup>, Fazlibegovic E<sup>C</sup>, Fonseca C<sup>C</sup>, Fruhwald F<sup>C</sup>, Gatzov P<sup>C</sup>, Goncalvesova E<sup>C</sup>, Hassanein M<sup>C</sup>, Hradec J<sup>C</sup>, Kavoliuniene A<sup>C</sup>, Lainscak M<sup>C</sup>, Logeart D<sup>C</sup>, Merkely B<sup>C</sup>, Metra M<sup>C</sup>, Persson S<sup>C</sup>, Seferovic P<sup>C</sup>, Temizhan A<sup>C</sup>, Tousoulis D<sup>C</sup>, Tavazzi L<sup>PI</sup>, Heart Failure Association of the ESC. (2013) Hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. *J Heart Fail*. 15(10):1173-84.
5. Zafrir B, Salman N, Crespo-Leiro MG, Anker SD, Coats AJ, Ferrari R, Filippatos G, Maggioni AP, Meloni M, Piepoli MF, Ruschitzka F, Paniagua-Martin MJ, Segovia J, Laroche C, **Amir O**. Heart Failure Long-Term Registry Investigators. (2016) Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*. 18(7):859-68.
6. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, **Amir O**, Logeart D, Dahlstrom U, Merkely B, Drazner M, J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A, Heart Failure Association of the European Society of Cardiology. (2016) European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *Eur J Heart Fail*. 18(6):613-25.
7. Elbaz-Greener G, Rahamim E, Abu Ghosh Z, Carasso S, Yarkoni M, Radhakrishnan S, Wijeyesundera I, Igor T, Planer D, Rozen G, **Amir O**. Sex difference and outcome trends following transcatheter aortic valve replacement. *Front Cardiovasc Med*. 2022 Oct 18;9:1013739.
8. Shahim B, Shahim A, Adamo M, Chioncel O, Benson L, Crespo-Leiro MG, Anker SD, Coats AJ, Filippatos G, Lainscak M, McDonagh T, Mebazaa A, Piepoli MF, Rosano GMC, Ruschitzka F, Savarese G, Seferovic P, Volterrani M, Crespo Leiro M, Segovia Cubero J, **Amir O**, Palic B, Maggioni AP, Metra M, Lund LH. Prevalence, characteristics and prognostic impact of aortic valve

disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2023 Jul;25(7):1049-1060.

9. Cooper TJ, Cleland JGF, Guazzi M, Pellicori P, Ben Gal T, **Amir O**, Al-Mohammad A, Clark McConnell A, Steine K, Dickstein K. Effects of sildenafil on symptoms and exercise capacity for failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial. Eur J Heart Fail. 2022 Jul;24(7):1239-1248.
10. **Amir O**, Amir RE, Paz H, Mor R, Sagiv M, Lewis BS. (2008) Aldosterone synthase gene polymorphism a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol.102(3):326-9.
11. Zafir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos S, Seferovic PM, Maggioni AP, De Mora Martin M, Polonski L, Silva-Cardoso J, **Amir O**, Investigators HHL-TR. (2018) Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 39(48):4277-4284.

**GOOGLE SCHOLAR H INDEX:**

H-index 36

i10-index 77

**Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society**  
*150 words maximum*

**2022-2024- European Heart Failure Society (ESC-HFA) Board Member**

**2021-2023- President, Israel Heart Society**

**2023-current- Head of the Israeli Chapter of the American college of Cardiology (ACC)**

**2022-2024-Quality of Heart Failure Care Centres Committee (HFA)**

**2022-2024- Member of the European Cardiology Society-European Heart Failure association**

**HFA Membership Committee**

**2024- Member of ICARe-HF - Improving Care through Accreditation and Recognition in Heart Failure**

**committee European Cardiology Society-European Heart Failure Association**

**Past National leader for the ESC-HF-LT registry**

**Past President National Israeli Heart Failure Society**

**Past Secretary National Israeli Heart Failure Society**

**Why are you motivated to join the HFA Board or Nominating Committee?**

*150 words maximum*

After more than 20 years engaging in the HF field, involved in clinical, scientific, academic and different positions in committees both national and international and serving as a board member of the HFA, I believe I may further contribute as Treasure in the next HFA assembly.,

During the years, being a president of the national HF society, the President of the National Heart Society and a director of heart institutes and HF units for more than 15 years, I delt with budgets, projects and I believe that I have the capability to cope with challenges of Treasure in the HFA board.

I have always collaborated with teams, colleges and other members and find it as a great advantage in planning strategies and execute them.

**How will you combine your HFA position with your daily clinical/research workload?**

*80 words maximum*

In the event I will be elected, I will prioritize my current main workload as the Director of the Heart Institute, Hadassah Medical Center, Jerusalem so I will be available for all the relevant tasks as Treasure.